250 related articles for article (PubMed ID: 11926745)
1. Cytomegalovirus drug resistance and clinical implications.
Chou SW
Transpl Infect Dis; 2001; 3 Suppl 2():20-4. PubMed ID: 11926745
[TBL] [Abstract][Full Text] [Related]
2. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
3. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.
Smith IL; Cherrington JM; Jiles RE; Fuller MD; Freeman WR; Spector SA
J Infect Dis; 1997 Jul; 176(1):69-77. PubMed ID: 9207351
[TBL] [Abstract][Full Text] [Related]
4. Progress in understanding cytomegalovirus drug resistance.
Emery VC
J Clin Virol; 2001 Jun; 21(3):223-8. PubMed ID: 11397658
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Ducancelle A; Belloc S; Alain S; Scieux C; Malphettes M; Petit F; Brouet JC; Sanson Le Pors MJ; Mazeron MC
J Clin Virol; 2004 Apr; 29(4):241-7. PubMed ID: 15018851
[TBL] [Abstract][Full Text] [Related]
6. Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Pérez JL
Microbiologia; 1997 Sep; 13(3):343-52. PubMed ID: 9353754
[TBL] [Abstract][Full Text] [Related]
7. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
8. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Chou S; Marousek G; Guentzel S; Follansbee SE; Poscher ME; Lalezari JP; Miner RC; Drew WL
J Infect Dis; 1997 Sep; 176(3):786-9. PubMed ID: 9291334
[TBL] [Abstract][Full Text] [Related]
9. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
11. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
12. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
Baldanti F; Lilleri D; Campanini G; Comolli G; Ridolfo AL; Rusconi S; Gerna G
J Antimicrob Chemother; 2004 Mar; 53(3):536-9. PubMed ID: 14739146
[TBL] [Abstract][Full Text] [Related]
13. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
14. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus drug resistance.
Emery VC
Antivir Ther; 1998; 3(4):239-42. PubMed ID: 10682146
[TBL] [Abstract][Full Text] [Related]
16. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
[TBL] [Abstract][Full Text] [Related]
17. Interpreting human cytomegalovirus antiviral drug susceptibility testing: the role of mixed virus populations.
Baldanti F; Biron KK; Gerna G
J Infect Dis; 1998 Mar; 177(3):823-4. PubMed ID: 9498475
[No Abstract] [Full Text] [Related]
18. Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Castagnola E; Miano M; Morreale G; Cristina E; Chierici M; Lanino E
Blood; 2001 Sep; 98(5):1627-8; author reply 1628-9. PubMed ID: 11547769
[No Abstract] [Full Text] [Related]
19. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Chou S; Marousek G; Li S; Weinberg A
J Clin Virol; 2008 Sep; 43(1):107-9. PubMed ID: 18502683
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Bruminhent J; Rotjanapan P; Watcharananan SP
Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
